Literature DB >> 16081018

The medial approach to triple arthrodesis. Indications and technique for management of rigid valgus deformities in high-risk patients.

Clifford L Jeng1, Anand M Vora, Mark S Myerson.   

Abstract

Between 1995 and 2002 the authors treated 17 patients who had a rigid hindfoot valgus deformity, and for whom a triple arthrodesis was planned, using a single medial incision. The indication for surgery was pain that was refractory to shoe wear, orthotic, and brace modifications. The severity of the hindfoot deformity itself was not a sufficient indication for this procedure. All 17 patients were examined a mean of 3.5 years following surgery (1-8 years). Subtalar and talonavicular arthrodesis was achieved in all patients and calcaneocuboid arthrodesis was achieved in 15 of 17 patients (2 asymptomatic pseudoarthrosis). The medial approach to triple arthrodesis is a reliable procedure, and can be used with a predictable outcome in patients who are at risk for wound healing complications for correction of hindfoot valgus deformity.

Entities:  

Mesh:

Year:  2005        PMID: 16081018     DOI: 10.1016/j.fcl.2005.04.004

Source DB:  PubMed          Journal:  Foot Ankle Clin        ISSN: 1083-7515            Impact factor:   1.653


  3 in total

1.  Primary Triple Arthrodesis for Management of Rigid Flatfoot Deformity.

Authors:  Jeffrey D Seybold; J Chris Coetzee
Journal:  JBJS Essent Surg Tech       Date:  2016-08-10

2.  Double hindfoot arthrodesis using a single-incision medial approach in the correction of adult-acquired flatfoot deformity: a case series.

Authors:  Gabriel Ferraz Ferreira; Natássia Nava; Thomas Stravinskas Durigon; Tatiana Ferreira Dos Santos; Miguel Viana Pereira Filho
Journal:  Int Orthop       Date:  2021-05-08       Impact factor: 3.075

3.  To evaluate the efficacy of Mobilization Techniques in Post-Traumatic stiff ankle with and without Paraffin Wax Bath.

Authors:  Sajid Rashid; Kamran Salick; Muhammah Kashif; Awad Ahmad; Kashif Sarwar
Journal:  Pak J Med Sci       Date:  2013-11       Impact factor: 1.088

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.